1162362
doi
10.5281/zenodo.1162362
oai:zenodo.org:1162362
user-sgc-opennotebook
user-openlabnotebooks
Bullock, Alex
Structural Genomics Consortium, University of Oxford
Optimising C2C12 muscle myoblast transfection with polyethylenimine (PEI) or Lipofectamine-2000
Brown, Elizabeth
Structural Genomics Consortium, University of Oxford
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
c2c12
myoblasts
transfection
optimisation
pEGFP-C1
<p>Optimisation of DNA transfection of the C2C12 muscle myoblast cell line, comparing use of polyethylenimine (PEI) and Lipofectamine-2000 with varying treatment conditions. </p>
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Zenodo
2018-01-29
info:eu-repo/semantics/other
1162361
user-sgc-opennotebook
user-openlabnotebooks
1579893896.767767
978600
md5:57550e38e150abeaca200002f539559a
https://zenodo.org/records/1162362/files/Optimising_C2C12_transfection_methods_20180129.pdf
public
10.5281/zenodo.1162361
isVersionOf
doi